Biopharmaceutical company ThromboGenics announced it intended to change its name to Oxurion NV to better reflect its activities and ambition to deliver eye disorder therapies.
Biopharmaceutical company TiGenix reported that the conditions for the €1.78 per share takeover bid by Japanese pharmaceutical company Takeda had been met with acceptance by 90.62% of security holders.
Biopharmaceutical company ThromboGenics reported it generated income of €9.1 million in 2017 compared to €7.1 million in 2016 and had advanced its pipeline of novel drug candidates for the treatment of diabetic eye disease.
Listed investment company Quest for Growth reported it had a strong 2017 with a profit of €27.4 million compared to €0.5 million in 2016.
Biopharmaceutical company TiGenix confirmed that Takeda Pharmaceutical Company intended to launch a cash takeover bid for TiGenix at a price of €1.78 per share.
Listed investment company Quest for Growth reported return on equity for the first months of 2017 was 20.6% with net asset value per share rising to €10.74 from €8.91 on 31 December 2016.
Biopharmaceutical company TiGenix reported revenue in the first half of 2017 was €0.6 million and it had made significant progress in its clinical programmes over the period.
Biopharmaceutical company ThromboGenics announced it will regain full global rights to its pharmacological treatment JETREA from Alcon, a Novartis company.
Biopharmaceutical company ThromboGenics reported revenue for the first half of 2017 was €2.7 million, including €1.9 million of product sales in the US and €0.8 million in royalty income, compared to €4.0 million in H1 2016.
Listed investment company Quest for Growth reported net asset value per share rose to €10.36 at 30 June 2017 from €8.91 as at 31 December 2016.